Mylotarg is an antibody-drug conjugate (ADC) targeting the CD33 antigen, used to treat CD33-positive acute myeloid leukemia (AML). As of 2025, the drug has not yet been launched in mainland China. Patients need to obtain the original drug through cross-border medical channels, and the price is greatly affected by market supply and demand and policies.

Latest price of Mylotarg in 2025

Original drug price and specifications

The Hong Kong version of Mylotarg produced by Pfizer in the United States has a specification of 5mg/bottle. The single treatment dose needs to be calculated based on the body surface area (BSA). The recommended dose for adults is 3mg/㎡, and the pediatric patient is adjusted to 0.1mg/kg. Since there are no generic drugs on the market, patients need to bear the full cost of treatment at their own expense.

Risk of cross-border drug purchase costs

Purchasing Mylotarg through medical institutions in Hong Kong or Turkey requires additional transportation costs (2-8℃ refrigeration throughout the journey), and the transportation cost increases by about 10%-15%. There is a risk of counterfeit drugs through personal channels. Some drugs may reduce their efficacy or deteriorate due to temperature control failure. It is recommended to purchase them through regular cross-border medical service institutions first.

After clarifying the price of the drug, patients need to pay attention to dietary management during treatment. The following content will explain the dietary precautions during the use of gemtuzumab.

Dietary precautions for Gemtuzumab(Mylotarg)

Gastrointestinal reactions and decreased immunity may occur during gemtuzumab treatment. Reasonable dietary adjustments can help alleviate adverse reactions and improve treatment tolerance.

Nutritional support during chemotherapy

During treatment, it is recommended to eat small meals frequently and choose high-protein, easily digestible foods (such as steamed eggs, tofu, and skinless chicken). Avoid spicy, fried or high-fiber foods to reduce intestinal irritation. Supplement at least 2000mL of water daily to prevent dehydration and drug-induced kidney injury. If severe vomiting occurs, oral rehydration salts can be used to maintain electrolyte balance.

Infection risk and dietary hygiene

Gemtuzumab may cause neutropenia and increase the risk of infection. Foods must be cooked thoroughly and raw seafood, unsterilized dairy products, and unwashed fruits and vegetables should be avoided. Tableware needs to be sterilized at high temperature, and hands should be washed strictly before and after meals to reduce the probability of gastrointestinal infection.

A scientific diet combined with standardized medication can improve the quality of life of patients. The following content will analyze the laboratory indicators that need to be monitored during treatment.

Laboratory abnormalities of Gemtuzumab

Gemtuzumab may cause abnormal laboratory indicators of multiple systems. Regular testing is the key to early detection and management of adverse reactions.

Liver function and blood cell monitoring

ALT, AST, total bilirubin and platelet count need to be tested before each administration. If ALT/AST increases by more than 3 times the normal value or platelets are <50×10⁹/L, treatment needs to be suspended. Venous occlusive liver disease (VOD) is a serious complication, manifested as ascites and liver pain, and requires early screening through ultrasound and liver elasticity testing.

Tracking of heart and electrolyte indicators

Gemtuzumab may prolong the QT interval. Electrocardiogram and blood potassium and magnesium levels need to be evaluated before treatment. If QTc>500ms or electrolyte disorder, it needs to be corrected before medication. During chemotherapy, check the echocardiogram monthly to monitor changes in ejection fraction and prevent the risk of cardiomyopathy.

During treatment, the 21-day dosing cycle must be strictly followed to avoid adjusting the dose without authorization. The drug preparation must be operated by professionals and infused in a light-proof manner using a 0.2-micron filter. If fever, chills or difficulty breathing occur, the infusion should be interrupted immediately and medical treatment should be sought. After opening, the drug solution must be used within 6 hours, and the remaining part cannot be stored. Through standardized treatment and close monitoring, Gemtuzumab can provide longer disease-free survival for CD33-positive AML patients.